LB Pharmaceuticals Inc (NASDAQ: LBRX) has filed an 8-K report detailing the retirement of Zachary Prensky from its Board of Directors. Effective March 13, 2026, Prensky will not seek reelection at the upcoming 2026 Annual Meeting of Stockholders. His term will conclude at that meeting, although he will continue to serve on the Board and the Nominating and Corporate Governance Committee until then. The company has confirmed that Prensky's decision to retire was not due to any disagreements regarding the company's operations or policies. Following his retirement, he is expected to provide consulting services to LB Pharmaceuticals. In connection with his departure, the company has entered into an Amendment No. 1 to the Transition, Separation, and Consulting Agreement, effective June 3, 2026. This amendment allows Prensky's outstanding and unvested stock options to continue vesting during the term of the agreement. The company expressed gratitude for Prensky's contributions during his tenure. This transition is part of LB Pharmaceuticals' ongoing governance and leadership strategy as it prepares for future growth and operational execution.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.